Flomax - Big Patent Expirations of 2010

Drug: Flomax (tamsulosin HCl)
Company: Boehringer Ingelheim
Indication: BPH
Expiration Date: Oct. 27, 2009/Pediatric Exclusivity through April 27

Scoop: Boehringer Ingelheim and Astellas face the loss of exclusivity for their Benign prostatic hyperplasia (BPH) drug Flomax this year. A top Ranbaxy executive has already said that his company will launch a generic version of Flomax in March, allowing the drugmaker to take advantage of its first-to-file status. Teva and Mylan are among the companies looking to sell their generic copies of the BPH drug. The '063 patent that is set to expire has pediatric exclusivity through April 27.

Flomax - Big Patent Expirations of 2010
Read more on

Suggested Articles

The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday.

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.